PIN3 COST-EFFECTIVENESS ANALYSIS OF COMBINED THERAPY WITH PEGINTERFERONALFA2A (40KD) (PEGASYS®) AND RIBAVIRIN (COPEGUS®) IN PATIENTS WITH CHRONIC C HEPATITIS (CHC)AND PERSISTENTLY NORMAL ALT LEVELS (PNALT)
Nov 1, 2005, 00:00
10.1016/S1098-3015(10)67312-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)67312-3/fulltext
Title :
PIN3 COST-EFFECTIVENESS ANALYSIS OF COMBINED THERAPY WITH PEGINTERFERONALFA2A (40KD) (PEGASYS®) AND RIBAVIRIN (COPEGUS®) IN PATIENTS WITH CHRONIC C HEPATITIS (CHC)AND PERSISTENTLY NORMAL ALT LEVELS (PNALT)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67312-3&doi=10.1016/S1098-3015(10)67312-3
First page :
Section Title :
Open access? :
No
Section Order :
545